<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187560</url>
  </required_header>
  <id_info>
    <org_study_id>LB-102-001</org_study_id>
    <nct_id>NCT04187560</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LB Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LB Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study&#xD;
      of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate&#xD;
      the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of&#xD;
      LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics&#xD;
      (PK) and pharmacodynamics (PD) of LB-102.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate&#xD;
      the safety, tolerability, and pharmacokinetics of LB-102 in healthy subjects. The study will&#xD;
      consist of two parts: Part A - Single Ascending Dose and Part B - Multiple Ascending Doses.&#xD;
      There will be 5 cohorts in Part A and 3 Cohorts in Part B of this study. Each cohort consists&#xD;
      of 8 subjects, with 6 subjects assigned to LB-102 and 2 subjects assigned to placebo.&#xD;
&#xD;
      In Parts A and B, eligible subjects will be randomized on Day 1 (pre-dose) to placebo (n=2)&#xD;
      or LB-102 (n=6). Eligible subjects will receive 1 dose on Day 1 (Part A) or 13 doses on Days&#xD;
      1-7 (Part B) of placebo or LB-102.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Actual">November 9, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)</measure>
    <time_frame>Day 8 (Part A) or Day 15 (Part B)</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration</measure>
    <time_frame>Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)</time_frame>
    <description>Time to reach the maximum observed plasma concentration for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration</measure>
    <time_frame>Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Cmax will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration</measure>
    <time_frame>Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to a drug from time 0 to time of the Last Quantifiable Concentration and will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose</measure>
    <time_frame>Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)</time_frame>
    <description>AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 14).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Part A Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB-102</intervention_name>
    <description>(N-Methyl amisulpride)</description>
    <arm_group_label>Part A Cohort 1</arm_group_label>
    <arm_group_label>Part A Cohort 2</arm_group_label>
    <arm_group_label>Part A Cohort 3</arm_group_label>
    <arm_group_label>Part A Cohort 4</arm_group_label>
    <arm_group_label>Part A Cohort 5</arm_group_label>
    <arm_group_label>Part B Cohort 6</arm_group_label>
    <arm_group_label>Part B Cohort 7</arm_group_label>
    <arm_group_label>Part B Cohort 8</arm_group_label>
    <other_name>Active Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be included in the study only if they meet all of the following criteria:&#xD;
&#xD;
          1. Competent to provide informed consent.&#xD;
&#xD;
          2. Voluntarily provide informed consent.&#xD;
&#xD;
          3. Healthy adult male and female subjects between 18 to 55 years of age inclusive at the&#xD;
             screening visit.&#xD;
&#xD;
          4. Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2 at screening visit.&#xD;
&#xD;
          5. Subjects must be in good general health as determined by medical history and physical&#xD;
             examination with no clinically significant medical findings and no history of&#xD;
             significant medical disease (e.g. cardiovascular, pulmonary, renal, etc.) or acute&#xD;
             condition with the past 30 days.&#xD;
&#xD;
          6. Have normal clinical laboratory test results and ECG, which are not considered to be&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
          7. Female subjects of child-bearing potential must agree to use two methods of an&#xD;
             acceptable method of birth control (e.g., condom and spermicide, intrauterine device&#xD;
             (IUD), oral contraception which has been stable for 30 days) and at least 90 days&#xD;
             after stopping the investigational product. Female subjects using oral contraception&#xD;
             whose partner consistently uses condoms or who is vasectomized is also acceptable.&#xD;
&#xD;
          8. Male subjects must be surgically sterile or practicing at least one method of&#xD;
             contraception, from initial study drug administration through 90 days after&#xD;
             administration of the last dose of study drug:&#xD;
&#xD;
          9. Male subjects must agree to abstain from sperm donation through 90 days after&#xD;
             administration of the last dose of investigational drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study for any of the following reasons:&#xD;
&#xD;
          1. Are pregnant or lactating.&#xD;
&#xD;
          2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, or neurological disorders which, in the opinion of the&#xD;
             investigator, increases the risk of the study drug or may confound the interpretation&#xD;
             of study measures.&#xD;
&#xD;
          3. Clinically significant abnormal findings on physical examination, vital signs, or ECG.&#xD;
&#xD;
          4. History or presence of psychiatric or neurological disease or condition.&#xD;
&#xD;
          5. History of seizures.&#xD;
&#xD;
          6. Subject with any history or current evidence of suicidal behavior.&#xD;
&#xD;
          7. Unwilling to complete any planned study assessments, including the Columbia-Suicide&#xD;
             Severity Rating Scale (CSSRS).&#xD;
&#xD;
          8. Recent history of alcohol or drug abuse (within the last two years).&#xD;
&#xD;
          9. Any use of tobacco or tobacco-containing products (cigarettes, pipes, etc.) within one&#xD;
             month prior to screening.&#xD;
&#xD;
         10. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
         11. Have received treatment with an investigational drug or device within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
         12. Use of any prescription or over the counter medication, herbal medications, vitamins,&#xD;
             or supplements within 14 days prior to study drug administration.&#xD;
&#xD;
         13. Have a positive test for human immunodeficiency virus (HIV) antibodies 1 and 2,&#xD;
             Hepatitis B surface antigen or Hepatitis C antibody.&#xD;
&#xD;
         14. Any subject who is known to be allergic to the study drug or any components of the&#xD;
             study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukasz Biernat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.LBPharma.us</url>
    <description>Corporate Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://lbpharma.us/wp-content/uploads/2020/12/lb-102-001-clinical-study-report-final.pdf</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

